1-20 of 38
Filip Janku
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)

Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah Drusbosky, Alice P Chen, Keyur Patel, Stanley R Hamilton, Mark Routbort, P. Mickey Williams, John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F Little, Carlos L Arteaga, Jeffrey S Abrams, Peter J O’Dwyer, Keith T Flaherty, Lyndsay N Harris, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B007.
https://doi.org/10.1158/1535-7163.TARG-23-B007
Published: 01 December 2023
View article titled, Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)
Journal Articles

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Filip Janku, Faye M. Johnson, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Martin Forester, Sarah P. Blagden, Andreas Wicki, Debora Schmitz, Alex A. Adjei
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B109.
https://doi.org/10.1158/1535-7163.TARG-19-B109
Published: 01 December 2019
View article titled, Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation
Journal Articles

Abstract B055: Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors

Filip Janku, Michael Birrer, Debra Richardson, Christina Chu, Sanjay Goel, Ying Su, Bahar Matin, Keisuke Kuida, Rodrigo Ruiz-Soto, Erika Paige Hamilton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B055.
https://doi.org/10.1158/1535-7163.TARG-19-B055
Published: 01 December 2019
View article titled, Abstract B055: Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors
Journal Articles

Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)

Ping Chi, Filip Janku, Michael Heinrich, Kristen Ganjoo, Hans Gelderblom, Michael Gordon, Robin Jones, Albiruni Razak, Jonathan Trent, Margaret von Mehren, Simin Hu, Ying Su, Rodrigo Ruiz-Soto, Suzanne George
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C077.
https://doi.org/10.1158/1535-7163.TARG-19-C077
Published: 01 December 2019
View article titled, Abstract C077: Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)
Journal Articles

Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors

Anthony W. Tolcher, Ryan J. Sullivan, Drew W. Rasco, Zeynep Eroglu, Nehal Lakhani, Dana Kessler, Helen Usansky, Sanjeeva Reddy, Louis J. Denis, Filip Janku
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): PR09.
https://doi.org/10.1158/1535-7163.TARG-19-PR09
Published: 01 December 2019
View article titled, Abstract PR09: Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
Journal Articles

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (6): 1149–1157.
https://doi.org/10.1158/1535-7163.MCT-18-1244
Published: 03 June 2019
View article titled, Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis
Open the PDF for Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis in another window
Journal Articles

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers

Roman Groisberg, David S. Hong, Jason Roszik, Filip Janku, Apostolia M. Tsimberidou, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (7): 1595–1601.
https://doi.org/10.1158/1535-7163.MCT-17-1107
Published: 01 July 2018
View article titled, Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Open the PDF for Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers in another window
Journal Articles

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas, Filip Janku
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (3): 671–676.
https://doi.org/10.1158/1535-7163.MCT-17-0673
Published: 28 February 2018
View article titled, Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
Open the PDF for Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers in another window
Journal Articles

Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

Sarina A. Piha-Paul, Wendy Wen Xiong, Tyler Moss, Rosa M. Mostorino, Shelby Sedelmeier, Kenneth Hess, Siqing Fu, David Hong, Filip Janku, Daniel Karp, Aung Naing, Shubham Pant, Jordi Rodon, Vivek Subbiah, A M. Tsimberidou, Timothy Yap, Milind Javle, Coya Tapia, Kenna R. Shaw, Karina Eterovic, Gordon B. Mills, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A096.
https://doi.org/10.1158/1535-7163.TARG-17-A096
Published: 01 January 2018
View article titled, Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in <em>BRCA1/2</em>, mutations/deletions in <em>PTEN</em> or PTEN loss, aberrations in other <em>BRCA</em> pathway genes, and germline mutations in <em>BRCA1/2</em> (not breast or ovarian cancer)
Journal Articles

Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors

Filip Janku, Ulka Vaishampayan, Vivek Khemka, Minny Bhatty, Chao Zhang, Henry H. Hsu, Paul S. Lin, Sandra Tong, Sunil Sharma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B176.
https://doi.org/10.1158/1535-7163.TARG-17-B176
Published: 01 January 2018
View article titled, Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors
Journal Articles

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina Piha-Paul, Roosevelt Anderson, Danxia Ke, Vincent Miller, Roman Yelensky, J. Jack Lee, David Hong, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (10): 2475–2485.
https://doi.org/10.1158/1535-7163.MCT-16-0196
Published: 02 October 2016
View article titled, <em>TP53</em> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Open the PDF for <em>TP53</em> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics in another window
Includes: Supplementary data
Journal Articles

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Filip Janku, Helen J. Huang, Bart Claes, Gerald S. Falchook, Siqing Fu, David Hong, Nishma M. Ramzanali, Giovanni Nitti, Goran Cabrilo, Apostolia M. Tsimberidou, Aung Naing, Sarina A. Piha-Paul, Jennifer J. Wheler, Daniel D. Karp, Veronica R. Holley, Ralph G. Zinner, Vivek Subbiah, Rajyalakshmi Luthra, Scott Kopetz, Michael J. Overman, Bryan K. Kee, Sapna Patel, Benoit Devogelaere, Erwin Sablon, Geert Maertens, Gordon B. Mills, Razelle Kurzrock, Funda Meric-Bernstam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (6): 1397–1404.
https://doi.org/10.1158/1535-7163.MCT-15-0712
Published: 02 June 2016
View article titled, <em>BRAF</em> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Open the PDF for <em>BRAF</em> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System in another window
Includes: Supplementary data
Journal Articles

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

Michelle L. Turski, Smruti J. Vidwans, Filip Janku, Ignacio Garrido-Laguna, Javier Munoz, Richard Schwab, Vivek Subbiah, Jordi Rodon, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (4): 533–547.
https://doi.org/10.1158/1535-7163.MCT-15-0643
Published: 05 April 2016
View article titled, Genomically Driven Tumors and Actionability across Histologies: <em>BRAF</em>-Mutant Cancers as a Paradigm
Open the PDF for Genomically Driven Tumors and Actionability across Histologies: <em>BRAF</em>-Mutant Cancers as a Paradigm in another window
Journal Articles

Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer

Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C50.
https://doi.org/10.1158/1535-7163.TARG-15-C50
Published: 01 December 2015
View article titled, Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer
Journal Articles

Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors

Jeffrey R. Infante, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Deborah J. Wong, Gerald S. Falchook, Manish Patel, Shubham Pant, Melinda Whiteside, Johanna C. Bendell, Todd M. Bauer, Filip Janku, Milind Javle, Rivka Colen, Nizar Tannir, Martin Oft
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A194.
https://doi.org/10.1158/1535-7163.TARG-15-A194
Published: 01 December 2015
View article titled, Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors
Journal Articles

Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors

Filip Janku, Roisin Connolly, Patricia LoRusso, Maya de Jonge, Ulka Vaishampayan, Jordi Rodon, Guillem Argilés, Andrea Myers, Shu-Fang Hsu Schmitz, Yan Ji, Margaret McLaughlin, Michael R. Palmer, Jennifer Morawiak
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C45.
https://doi.org/10.1158/1535-7163.TARG-15-C45
Published: 01 December 2015
View article titled, Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors
Journal Articles

Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers

Muhammad Rizwan Khawaja, Vinu Madhusudanannair, Chaan Ng, Alpa Nick, Filip Janku, Sarina Piha-Paul, Robert Coleman, Pamela Soliman, Siqing Fu, David Hong, Daniel Karp, Vivek Subbiah, Apostolia Tsimberidou, Funda Meric-Bernstam, Karen Lu, Aung Naing
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C44.
https://doi.org/10.1158/1535-7163.TARG-15-C44
Published: 01 December 2015
View article titled, Abstract C44: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced cancers
Journal Articles

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Van Morris, Filip Janku, Helen Huang, Siqing Fu, Michael Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia Tsimbierdou, David Fogelman, Imad Shurieqi, Shanequa Manuel, Antonio Scamardo, Richard Lanman, Nicolas Sommer, David Hong, Scott Kopetz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A36.
https://doi.org/10.1158/1535-7163.TARG-15-A36
Published: 01 December 2015
View article titled, Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer
Journal Articles

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

Tina Cascone, Kenneth R. Hess, Sarina Piha-Paul, David S. Hong, Michael Roxas, Ishwaria M. Subbiah, Siquing Fu, Aung Naing, Filip Janku, Daniel Karp, Steven I. Sherman, Funda Meric-Bernstam, John V. Heymach, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C17.
https://doi.org/10.1158/1535-7163.TARG-15-LB-C17
Published: 01 December 2015
View article titled, Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations
Journal Articles

Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents

Prasanth Ganesan, Stacy Moulder, J. Jack Lee, Filip Janku, Vicente Valero, Ralph G. Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric-Bernstam, Razelle Kurzrock, Jennifer J. Wheler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 3175–3184.
https://doi.org/10.1158/1535-7163.MCT-14-0358
Published: 04 December 2014
View article titled, Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Open the PDF for Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents in another window
Includes: Supplementary data